# A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation

> **NCT03439514** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 77 (actual)

## Conditions studied

- Dilated Cardiomyopathy
- Lamin A/C Gene Mutation

## Interventions

- **DRUG:** ARRY-371797 (PF-07265803)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03439514
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-17
- **Primary completion:** 2022-10-13
- **Final completion:** 2022-10-13
- **Target enrollment:** 77 (ACTUAL)
- **Why stopped:** The Sponsor terminated the study due to futility. The decision to stop the study was not based on safety concerns.
- **Last updated:** 2024-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03439514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03439514, "A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03439514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*